Actionable insights straight to your inbox

Equities logo

Stocks Under $10: Buy Rated Biomed/Genetics Companies in the Medical Space

At www.ValuEngine.com we show that the Medical sector 12.6% overvalued with the Medical Biomed/Genetics 15.4% overvalued. All six stocks in today’s table have complete ValuEngine data and have

At www.ValuEngine.com we show that the Medical sector 12.6% overvalued with the Medical Biomed/Genetics 15.4% overvalued. All six stocks in today’s table have complete ValuEngine data and have enough price data to have most value levels, risky levels and pivots.

Amarin Corp. plc (AMRN) – was a $43 stock in April 2007, and has been below $10 since the week of December 15, 2012.
Idenix Pharmaceuticals Inc. (IDIX) – was an $15 stock in January 2012, and has been below $10 since the week of August 11, 2012.
PDL BioPharma, Inc. (PDLI) – has been below $10 since the week of May 15, 2008.
Repligen Corp. (RGEN) – has been below $7.50 for at least five years.
RTI Biologics, Inc. (RTIX) – has been below $10 since the week of October 4, 2008.
Transition Therapeutics Inc. (TTHI) – has been below $10 since the week of August 9, 2008.

Reading the Table

OV / UN Valued – The stocks with a red number are undervalued by this percentage. Those with a black number are overvalued by that percentage according to ValuEngine. The most undervalued stock is AMRN by 57.7%. There are no overvalued stocks in today’s table.

VE Rating – A “1-Engine” rating is a Strong Sell, a “2-Engine” rating is a Sell, a “3-Engine” rating is a Hold, a “4-Engine” rating is a Buy and a “5-Engine” rating is a Strong Buy. One stock (AMRN) is rated a Strong Buy, while the other five are rated Buy.

Last 12-Month Return (%) – Stocks with a Red number declined by that percentage over the last twelve months. Stocks with a Black number increased by that percentage over the past twelve months! The biggest winner over the last twelve months is RGEN with a gain of 47.4%. The biggest loser was IDIX with a loss of 62.9%.

Forecast 1-Year Return – Stocks with a Red number are projected to decline by that percentage over the next twelve months. Stocks with a Black number in the Table are projected to move higher by that percentage over the next twelve months. These stocks are projected to be between 5.0% and 12.3% higher over the next twelve months.

P/E Ratios – The twelve month trailing P/E ratios; of the three stocks with a P/E ratio, PDLI has a single-digit P/E at 4.8.

Value Level: is the price at which to enter a GTC Limit Order to buy on weakness. The letters mean; W-Weekly, M-Monthly, Q-Quarterly, S-Semiannual and A- Annual.

Pivot: A level between a value level and risky level that acts as a magnet during the time frame noted.

Risky Level: is the price at which to enter a GTC Limit Order to sell on strength.

Where to Buy and Where to Sell

A “Value Level” is a price at which buyers should add to positions on market price weakness. A “Risky Level” is a price at which sellers should reduce holdings on market price gains. A “Pivot” is a support or resistance (Value Level or Risky Level) that was violated in its time horizon, acting as a magnet during the remainder of that time horizon.  These levels are calculated in weekly (W), monthly (M), quarterly (Q), semiannual (S) and annual (A) time horizons, based on the past nine closes in each time horizon. My theory is that the closes over a nine-year period are the summation of all bullish and bearish events for that market or specific stock. These levels are the most important element of my Buy and Trade Strategy.

Buy and Trade Guidelines

Investors should consider entering good until cancelled (GTC) orders to buy weakness to a value level, or to sell strength to a risky level.

if AI were the California Gold Rush, then NVIDIA would be the biggest seller of picks and shovels.